FDA-reviewed vitamin D products were calibrated around population averages. The RDA aims at the 25-hydroxyvitamin D level that keeps bone mineralization adequate in most replete adults, and the prescription 50,000 IU ergocalciferol capsule (Drisdol) was approved for a generic loading schedule that ignores the variables clinicians actually titrate against. Baseline 25-OH-D, body fat (vitamin D is fat-soluble and sequesters in adipose tissue), CYP2R1 and CYP27B1 genetics, kidney function, calcium and PTH status, magnesium repletion, age, latitude and sun exposure, and the specific reason for deficiency (malabsorption from celiac, Crohn's, gastric bypass, cystic fibrosis, cholestatic liver disease, versus simple sun avoidance) all move where a given patient lands at a given dose. The OTC 600 to 10,000 IU range covers most healthy adults, but it does not cover a 350-pound patient post Roux-en-Y with a 25-OH-D of 9, or a child on a ketogenic diet for refractory epilepsy, or an adult with documented soy and lanolin allergy who cannot tolerate the excipients in commercial softgels.
Compounding addresses the gaps the manufactured catalog leaves open. The molecule a 503A pharmacy dispenses is cholecalciferol or ergocalciferol or calcitriol, the same molecules the FDA reviewed, prepared at a strength and in a vehicle the commercial line does not stock. High-dose loading regimens can be dispensed as a custom 50,000 IU prescription strength on a schedule the prescriber chose rather than the one printed on the Drisdol label, with concurrent vitamin K2 or magnesium where the clinician wants them. Liposomal and oil-emulsion vehicles raise bioavailability in patients with fat malabsorption who do not respond to standard softgels, and IM stoss preparations bypass the gut entirely when oral routes are not viable. Lanolin-free D2 and soy-free, dye-free, preservative-free formulations exist because some patients react to the excipients in every commercial D3 softgel on the shelf. None of that is reachable through the OTC aisle.
This is the older arrangement, a pharmacist filling a named prescription for a named patient against a documented clinical reason. Modern state inspection, USP standards, and the 503A patient-specific rule keep it accountable rather than replacing it.
In brief
High-Dose Vitamin D Explained
Vitamin D is a fat-soluble vitamin and pro-hormone that helps the body absorb calcium and keep bones healthy. The body can make vitamin D in skin exposed to sunlight, and small amounts come from food. Supplements come in two main forms: vitamin D3 (cholecalciferol, made from sheep wool or plant sources) and vitamin D2 (ergocalciferol, made from yeast). D3 raises blood levels more efficiently than D2 5.
Most adults need somewhere between 600 and 2,000 IU per day. Vitamin D3 in those everyday amounts is sold over the counter and does not need a prescription. Compounded vitamin D from a pharmacy is reserved for patients who cannot use the over-the-counter products, for example, people with cystic fibrosis or after weight-loss surgery whose intestines do not absorb fat-soluble vitamins, children who need a custom liquid dropper, or people whose doctor wants a very specific dose or an injection 1. Calcitriol (Rocaltrol) and similar analogs are prescription-only because they bypass the body's normal regulation and are reserved for kidney disease 4. The NIH Office of Dietary Supplements health-professional fact sheet 38 is a useful patient-facing reference for everyday supplementation questions 2.
At a glance
Quick Facts About High-Dose Vitamin D
Category
Fat-soluble secosteroid pro-hormone (vitamin D family)
Active ingredients
Cholecalciferol (vitamin D3), ergocalciferol (vitamin D2), calcitriol (1,25-dihydroxyvitamin D3), and the analog doxercalciferol (1α-hydroxyvitamin D2)
FDA-approved branded forms
Drisdol (ergocalciferol 50,000 IU capsule, prescription); Rocaltrol/Calcijex (calcitriol oral and injectable, prescription for renal osteodystrophy and hypocalcemia); Hectorol (doxercalciferol, prescription for secondary hyperparathyroidism in CKD)
OTC overlap
Cholecalciferol (D3) is sold over-the-counter as a dietary supplement at strengths up to 50,000 IU per softgel. Most patients meeting RDAs do not need a compounded preparation.
Routes
Oral (capsule, softgel, liquid, troche, sublingual), intramuscular injection (high-dose stoss), and topical/transdermal in limited compounded contexts
Evidence posture
Mechanistic biology and the 25-hydroxyvitamin D dose-response are well established. Large RCTs of supplementation in replete adults (VITAL, ViDA, D-Health, DO-HEALTH, VIDA, D2d) have been largely null for cancer, cardiovascular events, fractures, and progression to diabetes in unselected populations; replacement in documented deficiency remains supported.
Conflicting guideline thresholds
The IOM (Ross 2011) set the RDA at 600 IU/day (ages 1, 70) and 800 IU/day (>70) with a sufficiency threshold of 20 ng/mL serum 25-OH-D. The Endocrine Society (Holick 2011) defined deficiency as <20 ng/mL and insufficiency as 21, 29 ng/mL, with target >30 ng/mL and higher replacement doses. The 2024 Endocrine Society guideline (Demay) walked back routine 25-OH-D screening and empiric supplementation in generally healthy adults.
Compounded under
503A, patient-specific prescription only, typically when an OTC oral cholecalciferol cannot meet the patient's documented absorption, dose, or formulation need
Toxicity range
Hypervitaminosis D (hypercalcemia, hypercalciuria, nephrocalcinosis) is associated with chronic intake far above the tolerable upper intake of 4,000 IU/day in adults and serum 25-OH-D typically >150 ng/mL; case reports of toxicity follow megadose dispensing errors and unlabeled product errors.
Prescription review
Patient-Specific Prescription Only
High-Dose Vitamin D on this page is a 503A compounded preparation. Every dose is made on a prescription, for a named patient, by a licensed pharmacist. It is not a stocked, mass-manufactured product.
Made to order, not off a shelf. No batch sits in a warehouse waiting for buyers. Your prescription is what triggers the prep.
Named-patient label. The bottle carries your name. The batch records carry your prescription.
Dose, strength, and route chosen for you. A prescriber who knows your chart decides what gets compounded, not a manufacturer who set the strength for a trial population.
Licensed pharmacist on the hook. A real person, with a license that can be pulled, signs off on every prep. State inspectors check the facility.
Compounded drugs are not FDA-approved. They should not be evaluated using branded-drug trial data. Availability varies by state and prescribed medication.
A research-use-only website ships a vial from a warehouse. There is no prescription, no pharmacist, no facility inspection, and no way to recall the product if something is wrong with it. If the vial is mislabeled, contaminated, or under-potent, there is nobody whose license is at stake.
A 503A compounding pharmacy is the other thing. Your doctor writes the prescription. A licensed pharmacist, whose name is on the label, prepares the medicine in a facility the state inspects. If something goes wrong, there is a person and a license on the hook, and a documented chain of custody on every lot. That accountability is what makes it safe.
What it is
What is High-Dose Vitamin D?
Vitamin D refers to a family of fat-soluble secosteroids, open-ring steroid molecules, that share a common 1,25-dihydroxyvitamin D pathway endpoint. The two parental forms are cholecalciferol (vitamin D3), produced in mammalian skin from 7-dehydrocholesterol under UVB exposure, and ergocalciferol (vitamin D2), produced in fungi and yeast from ergosterol 27. Both are biologically inert until activated by sequential hydroxylation 1.
The activated hormone calcitriol (1,25-dihydroxyvitamin D3) acts through the nuclear vitamin D receptor (VDR) to regulate transcription at thousands of genomic sites involved in calcium and phosphate handling, bone remodeling, and immune modulation 28. The storage and clinically measured form is 25-hydroxyvitamin D (25-OH-D, calcidiol); the 1,25-dihydroxy form is reserved for specific clinical scenarios (CKD evaluation, granulomatous disease, hereditary 1α-hydroxylase deficiency) 1.
FDA-regulated products include over-the-counter cholecalciferol dietary supplements (up to 50,000 IU per softgel), prescription ergocalciferol (Drisdol, 50,000 IU per capsule), prescription calcitriol (Rocaltrol oral and Calcijex IV) for hypocalcemia and renal osteodystrophy, and prescription doxercalciferol (Hectorol) for secondary hyperparathyroidism in chronic kidney disease 282729. Compounded preparations under 503A occupy a narrow niche addressing specific absorption, dose, or formulation needs not met by these manufactured products.
How it works
How High-Dose Vitamin D Works
Class
Fat-soluble vitamin / pro-hormone
First studied
1920s-30s anti-rachitic research
Common forms
Oral capsule, injection
Compounding category
503A, patient-specific prescription
Vitamin D operates through a two-step activation pathway. Cholecalciferol (D3) or ergocalciferol (D2) enters the circulation from skin, diet, or supplementation, where it is bound to vitamin D binding protein (DBP) and 25-hydroxylated in the liver primarily by CYP2R1 to 25-hydroxyvitamin D, the dominant circulating form and the standard clinical measurement of vitamin D status. A second hydroxylation by CYP27B1 (1α-hydroxylase) in the proximal renal tubule produces 1,25-dihydroxyvitamin D (calcitriol), the biologically active hormone 1.
Calcitriol binds the nuclear vitamin D receptor (VDR), heterodimerizes with retinoid X receptor (RXR), and regulates transcription of genes involved in intestinal calcium absorption (TRPV6, calbindin), renal calcium reabsorption, bone mineralization, parathyroid hormone suppression, and immune cell differentiation. The parathyroid axis tightly regulates the system: low serum calcium raises PTH, which stimulates CYP27B1 to produce more calcitriol, which then raises intestinal calcium absorption and suppresses PTH back to baseline 1.
FGF-23, produced by osteocytes in response to phosphate load and calcitriol itself, inhibits CYP27B1 and stimulates CYP24A1 (24-hydroxylase) to inactivate 25-OH-D and 1,25-(OH)2-D, preventing toxicity. Loss-of-function CYP24A1 mutations cause idiopathic infantile hypercalcemia, and granulomatous diseases (sarcoidosis, tuberculosis) generate extrarenal calcitriol from macrophage CYP27B1 that escapes normal feedback, both clinical scenarios where the active 1,25-(OH)2-D level matters more than 25-OH-D.
Research history
High-Dose Vitamin D Research History
Vitamin D was discovered in the early 20th century as the anti-rachitic factor in cod liver oil. McCollum, Mellanby, and others established by the 1920s that a fat-soluble factor distinct from vitamin A reversed rickets, and Windaus's 1928 Nobel Prize work characterized the sterol precursors. Fortification of milk with vitamin D (initially via irradiated ergosterol, later cholecalciferol) effectively eliminated rachitic disease in the industrialized world by mid-century. DeLuca's work in the 1960s, 70s identified the renal 1α-hydroxylation step and active 1,25-dihydroxyvitamin D hormone, and the cloning of the VDR in 1988 placed vitamin D firmly in the nuclear hormone receptor superfamily 17.
Holick's 2007 New England Journal of Medicine review 1 crystallized modern clinical understanding: the worldwide prevalence of low 25-OH-D, the dual D2/D3 supplementation landscape, the dose-response evidence summarized by Heaney 2003 6 and the comparative efficacy of D3 over D2 from Trang 1998 5, and the early observational signals for non-skeletal disease prevention 17. In 2010, 2011 two guideline bodies issued conflicting recommendations: the Institute of Medicine (Ross et al., 2011) 2 set the RDA at 600, 800 IU/day with a 20 ng/mL sufficiency threshold and a tolerable upper intake of 4,000 IU/day, on the grounds that skeletal endpoints were the only adequately RCT-supported outcome. The Endocrine Society (Holick et al., 2011) 3 defined deficiency as <20 ng/mL and insufficiency as 21, 29 ng/mL with a >30 ng/mL target, citing parathyroid suppression and observational outcome data.
The decade after 2011 produced the largest vitamin D supplementation RCTs ever conducted 17. The Trivedi 2003 BMJ trial 10 of 100,000 IU four-monthly oral cholecalciferol had earlier reported a modest reduction in fractures, but the Sanders 2010 JAMA trial 11 of an annual 500,000 IU bolus paradoxically increased falls and fractures, raising concern about pulse-dose pharmacology. VITAL (Manson 2019 19, LeBoff 2022 20) randomized 25,871 generally healthy U.S. adults to 2,000 IU/day cholecalciferol or placebo and reported null primary results for invasive cancer, major cardiovascular events, and incident fracture. ViDA (Scragg 2017 21, Khaw 2017 22) randomized 5,108 New Zealand adults to monthly 100,000 IU or placebo and was null for cardiovascular disease and falls/non-vertebral fractures. D2d (Pittas 2019 23) randomized 2,423 adults at high diabetes risk to 4,000 IU/day or placebo and was null for progression to type 2 diabetes. DO-HEALTH (Bischoff-Ferrari 2020 24) randomized 2,157 healthy older adults across Europe and was null on a composite of musculoskeletal and cognitive endpoints.
Earlier supplementation results were more positive in specific populations. Bischoff-Ferrari's 2009 BMJ meta-analysis 12 of falls and the 2012 NEJM pooled analysis 13 of fractures supported a dose-dependent reduction in falls and non-vertebral fractures at higher daily doses (≥800 IU/day) in vitamin-D-deficient elderly. Avenell's 2014 Cochrane review 34 integrated 53 RCTs and supported vitamin D plus calcium for hip and any-fracture reduction in institutionalized older adults while showing little effect of vitamin D alone in community-dwelling adults. Lappe's 2017 JAMA trial 25 of vitamin D plus calcium for cancer prevention in older women was null on the primary endpoint. Bolland's 2018 Lancet Diabetes and Endocrinology meta-analysis 26 integrated 81 RCTs and concluded that vitamin D supplementation does not prevent fractures, falls, or improve bone density in unselected adults 173635. Pregnancy supplementation evidence (Hollis 2011 14) supported 4,000 IU/day as safer and more effective at achieving sufficiency than 400 IU/day, without adverse maternal or fetal outcomes. RTI prevention meta-analyses 16 found a small protective effect concentrated in deficient patients on daily dosing. The Murai 2021 JAMA trial 18 of a single 200,000 IU bolus in hospitalized moderate-to-severe COVID-19 was null on length of stay. Regional guideline statements 37 sit between the IOM and Endocrine Society 2011 thresholds.
The 2024 Endocrine Society guideline 4 formalized the retreat from broad screening and empiric supplementation: it no longer recommends routine 25-OH-D measurement in generally healthy adults, no longer recommends empiric supplementation above the IOM RDA, and reserves higher-dose supplementation for specific risk groups (children 1, 18 for rickets prevention, pregnant individuals, adults ≥75 for skeletal benefit, prediabetes) 17. The compounded 503A role was not addressed because compounding is regulated separately.
Timeline
High-Dose Vitamin D Timeline
1922McCollum identifies the fat-soluble anti-rachitic factor in cod liver oil and names it vitamin D, distinguishing it from vitamin A
1928Adolf Windaus awarded the Nobel Prize in Chemistry for the structural elucidation of the sterol precursors of vitamin D
1932Cholecalciferol (vitamin D3) and ergocalciferol (vitamin D2) chemically distinguished; commercial fortification of milk begins in the U.S.
1971DeLuca and colleagues identify 1,25-dihydroxyvitamin D as the biologically active hormone produced by renal 1α-hydroxylation
1988Cloning of the human vitamin D receptor (VDR) places vitamin D in the nuclear hormone receptor superfamily
1998Trang et al 5. publish in Am J Clin Nutr that cholecalciferol (D3) raises serum 25-OH-D approximately twice as efficiently as ergocalciferol (D2) at equimolar dosing
2003Heaney et al 6. publish in Am J Clin Nutr the dose-response curve of serum 25-OH-D to oral cholecalciferol, approximately 0.7 ng/mL per 100 IU/day at steady state
2003Trivedi et al 10. publish in BMJ the four-monthly 100,000 IU oral cholecalciferol RCT (N=2,686) showing a modest reduction in non-vertebral fractures in community-dwelling adults
2007Holick publishes the canonical Vitamin D Deficiency review in the New England Journal of Medicine 1
2007Hathcock, Shao, Vieth, and Heaney publish in Am J Clin Nutr a risk assessment for vitamin D, supporting a tolerable upper intake of 10,000 IU/day in adults 7
2008Aloia et al. publish in Am J Clin Nutr the intake needed to reach defined serum 25-OH-D thresholds; Misra et al 89. publish in Pediatrics the pediatric vitamin D deficiency management consensus
2009Bischoff-Ferrari et al 12. publish in BMJ a meta-analysis of fall prevention, supporting a dose-dependent reduction with vitamin D ≥800 IU/day in older adults
2010Sanders et al 11. publish in JAMA an RCT of annual 500,000 IU oral cholecalciferol in older women, paradoxically increased falls and fractures, undermining annual-bolus pharmacology
2011Institute of Medicine report (Ross et al., JCEM summary) sets the vitamin D RDA at 600, 800 IU/day with a 20 ng/mL sufficiency threshold and a 4,000 IU/day tolerable upper intake 2
2011Endocrine Society guideline (Holick et al., JCEM) defines deficiency as <20 ng/mL and insufficiency as 21, 29 ng/mL with a >30 ng/mL target, conflicting with the IOM thresholds 3
2011Hollis et al 1415. publish the pregnancy supplementation RCT in J Bone Miner Res, 4,000 IU/day safe and more effective at achieving 25-OH-D sufficiency than 400 IU/day; the accompanying review summarizes pregnancy requirements
2012Bischoff-Ferrari et al 13. publish in NEJM the pooled analysis of vitamin D dose requirements for fracture prevention, dose-dependent reduction at the highest intake quartile
2017Lappe et al 25. publish in JAMA the calcium plus vitamin D vs placebo cancer prevention RCT in older women, null primary endpoint
2017Martineau et al 16. publish in BMJ the individual-participant-data meta-analysis of vitamin D for acute respiratory tract infections, modest protective effect concentrated in deficient patients on daily dosing
2017Scragg et al. publish ViDA (JAMA Cardiology), monthly 100,000 IU vitamin D over a median 3.3 years null for cardiovascular disease in 5,108 NZ adults; Khaw et al 2122. publish secondary outcomes (Lancet Diab Endocrinol), null for falls and non-vertebral fractures
2018Bolland et al 26. publish in Lancet Diabetes and Endocrinology a meta-analysis of 81 RCTs concluding vitamin D supplementation does not prevent fractures or falls in unselected adults
2019Manson et al 19. publish in NEJM the VITAL primary results, 2,000 IU/day cholecalciferol in 25,871 U.S. adults over 5.3 years was null for invasive cancer and major cardiovascular events
2019Pittas et al 23. publish D2d in NEJM, 4,000 IU/day cholecalciferol in 2,423 adults at high diabetes risk null for progression to type 2 diabetes
2020Bischoff-Ferrari et al 24. publish DO-HEALTH in JAMA, 2,000 IU/day vitamin D, omega-3, and home exercise in 2,157 generally healthy older adults null on a composite of musculoskeletal and cognitive function endpoints
2021Murai et al 18. publish in JAMA an RCT of a single 200,000 IU oral cholecalciferol dose in hospitalized moderate-to-severe COVID-19, null on hospital length of stay
2021Jolliffe et al 17. publish in Lancet Diabetes and Endocrinology an updated aggregate-data meta-analysis of vitamin D for acute respiratory infections, small protective effect on daily low-dose regimens
2022LeBoff et al 20. publish in NEJM the VITAL fracture ancillary, 2,000 IU/day cholecalciferol over a median 5.3 years null for incident fracture in midlife and older adults
2024Demay et al 4. publish the updated Endocrine Society guideline in JCEM, retreats from routine 25-OH-D screening and broad empiric supplementation in generally healthy adults
Natural role
Biological Role of High-Dose Vitamin D
Vitamin D is the master regulator of calcium and phosphate homeostasis. Through intestinal calcium absorption (active, calcitriol-driven, ~30, 40% of dietary calcium at sufficiency; ~10, 15% at deficiency), renal calcium and phosphate reabsorption, and PTH suppression at the parathyroid gland, the vitamin D system protects against hypocalcemia and supports adequate substrate for bone mineralization. Severe deficiency in children causes rickets (failure of growth plate mineralization), and in adults causes osteomalacia (failure of osteoid mineralization with characteristic Looser zones on imaging) 124.
Beyond skeleton: VDR is expressed in most nucleated cells, and 1,25-(OH)2-D modulates innate immune defense (induction of cathelicidin in monocytes and macrophages), adaptive immunity (T-cell differentiation), insulin secretion, and renin-angiotensin axis regulation. These non-skeletal effects motivated more than two decades of observational studies linking low 25-OH-D to cancer, cardiovascular disease, autoimmunity, diabetes, and infection 19214. Mendelian randomization and the large supplementation RCTs have repeatedly failed to confirm these associations as causal in unselected populations 23.
Clinical contexts studied
Clinical Contexts for High-Dose Vitamin D
Hypocalcemia in chronic kidney disease and renal osteodystrophy fda approved
FDA-approved indication for manufactured calcitriol (Rocaltrol oral / Calcijex IV) and doxercalciferol (Hectorol). The diseased renal 1α-hydroxylation step justifies use of the active hormone or 1α-pre-hydroxylated analog rather than parental D2/D3.
Calcitriol (Rocaltrol oral capsule and oral solution; Calcijex IV) is FDA-approved for the management of hypocalcemia in patients on chronic dialysis and for secondary hyperparathyroidism associated with stage 3 or 4 chronic kidney disease. Doxercalciferol (Hectorol oral capsule and IV solution) is FDA-approved for secondary hyperparathyroidism in CKD stage 3, 4, and dialysis 2829. These products bypass the diseased renal 1α-hydroxylation step.
Vitamin D deficiency replacement (50,000 IU weekly prescription regimen) fda approved
FDA-approved indication for prescription ergocalciferol (Drisdol) at 50,000 IU per capsule for documented deficiency, refractory rickets, and familial hypophosphatemia. Cholecalciferol at the same nominal strength is available OTC as a dietary supplement.
Drisdol (ergocalciferol 50,000 IU capsule) is FDA-approved for the treatment of vitamin D deficiency, refractory rickets (vitamin D resistant rickets), and familial hypophosphatemia. Typical dosing for adult deficiency is 50,000 IU weekly for 8, 12 weeks until 25-OH-D reaches sufficiency, then maintenance 273. The Endocrine Society 2011 guideline supports this regimen; the 2024 update 4 notes that equivalent OTC cholecalciferol dosing is generally preferred on PK grounds 5.
Documented 25-OH-D deficiency (<20 ng/mL) in adults well studied
Well-supported by guideline consensus despite the null large-RCT supplementation literature in replete populations. Replacement therapy until sufficiency is achieved is consensus practice.
Both the IOM 2011 2 and Endocrine Society 2011 3 guidelines agreed that documented serum 25-OH-D <20 ng/mL warrants supplementation in all age groups, even though they differed on the sufficiency target above 20 ng/mL. The Heaney 2003 dose-response data 6 support ~100 IU/day of cholecalciferol per 0.7 ng/mL increment in steady-state 25-OH-D. The 2024 Endocrine Society guideline 4 reaffirmed replacement of documented deficiency while retreating from empiric screening.
Fall and fracture prevention in vitamin-D-deficient older adults well studied
Supported in earlier meta-analyses concentrated on deficient elderly; null in modern supplementation trials in replete populations.
Bischoff-Ferrari's 2009 BMJ meta-analysis 12 of 8 RCTs reported a 19% reduction in falls with vitamin D ≥700 IU/day in older adults. The 2012 NEJM pooled analysis 13 of 11 RCTs (N=31,022) reported a 30% reduction in hip fracture and 14% in non-vertebral fracture at the highest intake quartile (median 800 IU/day). However, the Sanders 2010 annual-bolus trial 11 paradoxically increased falls and fractures, and Bolland's 2018 81-trial meta-analysis 26 in unselected adults was null. The VITAL fracture ancillary 20 and ViDA falls outcomes 22 were null in replete populations. Net interpretation: replacement in deficient elderly retains support; broad empiric supplementation in replete adults does not.
Acute respiratory tract infection prevention well studied
Studied in two large IPD-style meta-analyses; modest protective effect concentrated in deficient patients on daily low-dose regimens.
Martineau et al. (2017) BMJ individual-participant-data meta-analysis 16 of 25 RCTs (N=10,933) reported a small reduction in acute respiratory tract infection (adjusted OR 0.88, 95% CI 0.81, 0.96) overall, with larger effect in baseline 25-OH-D <25 nmol/L (~10 ng/mL) on daily or weekly low-dose regimens. The Jolliffe 2021 update 17 of 46 RCTs (N=75,541) confirmed a small protective effect on daily low-dose dosing. The Murai 2021 JAMA trial 18 of a single 200,000 IU dose in hospitalized moderate-to-severe COVID-19 was null on hospital length of stay.
Cancer and cardiovascular disease prevention in generally healthy adults well studied
Tested in the largest vitamin D supplementation RCTs; null on hard primary endpoints. No longer a guideline-supported indication.
VITAL 19 randomized 25,871 generally healthy U.S. adults aged ≥50 (men) and ≥55 (women) to 2,000 IU/day cholecalciferol or placebo for a median 5.3 years and reported null primary results for invasive cancer (HR 0.96, 95% CI 0.88, 1.06) and major cardiovascular events (HR 0.97, 95% CI 0.85, 1.12). ViDA 21 randomized 5,108 NZ adults to monthly 100,000 IU and was null for incident cardiovascular events. Lappe 2017 25 randomized 2,303 older women to vitamin D plus calcium and was null for cancer incidence. The 2024 Endocrine Society guideline 4 explicitly does not recommend empiric vitamin D supplementation above the IOM RDA for cancer or cardiovascular prevention in generally healthy adults.
Prevention of progression to type 2 diabetes in prediabetes well studied
Tested in the dedicated D2d trial; null on primary endpoint with possible benefit in deficient subgroups. The 2024 Endocrine Society guideline gives a conditional recommendation in prediabetes.
D2d 23 randomized 2,423 adults at high diabetes risk to 4,000 IU/day cholecalciferol or placebo for a median 2.5 years and reported HR 0.88 (95% CI 0.75, 1.04, P=0.12) for progression to diabetes, null on the prespecified primary endpoint. The 2024 Endocrine Society guideline 4 gives a conditional recommendation for vitamin D in adults with prediabetes based on D2d secondary and pooled-trial analyses.
Studied in dedicated RCTs; safer and more effective at achieving 25-OH-D sufficiency at 4,000 IU/day than the standard prenatal 400 IU/day. The 2024 Endocrine Society guideline supports supplementation above the standard prenatal dose in pregnancy.
Hollis et al. (2011) 14 randomized 494 pregnant women to 400, 2,000, or 4,000 IU/day cholecalciferol from 12, 16 weeks gestation through delivery. The 4,000 IU/day arm achieved 25-OH-D sufficiency in 82% vs 50% of the 400 IU/day arm without adverse maternal or neonatal events; cord blood 25-OH-D rose in parallel. The 2011 review 15 consolidated requirements. The 2024 Endocrine Society guideline 4 supports daily supplementation above the standard prenatal 400 IU/day in pregnant individuals.
Pediatric rickets prevention and treatment well studied
Standard-of-care; 400 IU/day from birth for infants and 600 IU/day for children 1, 18 per IOM and the 2024 Endocrine Society guideline.
Misra et al. (2008) 9 consolidated the Lawson Wilkins Pediatric Endocrine Society consensus on pediatric vitamin D deficiency and rickets management: 400 IU/day from birth in breast-fed infants, 600 IU/day in children 1, 18, and treatment of established deficiency with 2,000, 6,000 IU/day cholecalciferol for 6, 12 weeks. The Demay 2024 4 guideline reaffirms these targets for rickets prevention in children 1, 18 and additionally supports higher empiric supplementation in this age group for non-skeletal endpoints.
Off-label use
Off-Label Uses of High-Dose Vitamin D
Stoss therapy, single or quarterly high-dose cholecalciferol for adherence-limited deficiency well studied
Off-label use of the FDA-approved Drisdol 50,000 IU capsule and OTC cholecalciferol. Risk profile depends on bolus size, annual 500,000 IU paradoxically harmful 11; four-monthly 100,000 IU acceptable 10.
Stoss therapy denotes large-bolus vitamin D dosing to rapidly correct deficiency or simplify adherence in selected populations (institutionalized elderly, intellectual disability, refugee health). Trivedi 2003 10 supported a four-monthly 100,000 IU regimen with a modest fracture reduction. Sanders 2010 11 tested an annual 500,000 IU bolus in older women and paradoxically increased falls and fractures, suggesting that the safety margin narrows as bolus size grows. Compounded IM stoss preparations (e.g., 300,000, 600,000 IU IM) may be appropriate for documented severe deficiency in malabsorption phenotypes where oral therapy is not reliable.
Replacement in malabsorption (cystic fibrosis, post-bariatric surgery, short bowel, fat malabsorption) well studied
Off-label use of high-dose oral cholecalciferol or compounded oily/liposomal vehicles to overcome impaired fat-soluble vitamin uptake.
Patients with cystic fibrosis, after Roux-en-Y gastric bypass or biliopancreatic diversion, with short bowel syndrome, or with chronic pancreatic insufficiency commonly fail to maintain 25-OH-D sufficiency on standard daily oral dosing. Replacement frequently requires 10,000, 50,000 IU/day cholecalciferol with serum monitoring 3; oil-based or liposomal compounded vehicles, or IM cholecalciferol, may improve bioavailability when oral fat absorption is severely impaired. The 2024 Endocrine Society guideline 4 does not specifically address malabsorption phenotypes but supports replacement to documented sufficiency.
FDA-approved use
FDA-Approved Uses of High-Dose Vitamin D
Brand
Indication
Year
Route
Drisdol
Vitamin D deficiency, refractory rickets, familial hypophosphatemia (ergocalciferol 50,000 IU oral capsule)
1941
Oral
Rocaltrol / Calcijex
Hypocalcemia in patients on chronic renal dialysis; management of secondary hyperparathyroidism in stage 3 or 4 chronic kidney disease (calcitriol, oral capsule/solution and IV injection)
1978
Oral and intravenous
Hectorol
Secondary hyperparathyroidism in adults with stage 3, 4, or dialysis-dependent chronic kidney disease (doxercalciferol, oral capsule and IV solution)
1999
Oral and intravenous
OTC cholecalciferol (D3)
Dietary supplement for the maintenance of normal vitamin D status. Not a prescription product; not FDA-evaluated for therapeutic claims under the DSHEA framework. Strengths up to 50,000 IU per softgel are sold over the counter.
DSHEA (1994) regulatory framework
Oral
The FDA-approved prescription vitamin D products are Drisdol (ergocalciferol 50,000 IU capsule), Rocaltrol/Calcijex (calcitriol oral and IV), and Hectorol (doxercalciferol). Calcitriol and doxercalciferol are pre-hydroxylated active analogs reserved for chronic kidney disease, where renal 1α-hydroxylation is impaired. OTC cholecalciferol is regulated as a dietary supplement under DSHEA and is sold at strengths up to 50,000 IU per softgel without prescription 272829.
Two guideline statements in 2011 created conflicting reference frames. The IOM (Ross 2011) 2 set the RDA at 600 IU/day for ages 1, 70 and 800 IU/day for >70, with a 20 ng/mL serum 25-OH-D sufficiency threshold and a 4,000 IU/day tolerable upper intake, derived from skeletal endpoints. The full IOM 2011 report 39 is the source-of-record. The Endocrine Society (Holick 2011) 3 defined deficiency as <20 ng/mL and insufficiency as 21, 29 ng/mL, with a >30 ng/mL target, citing parathyroid suppression and observational outcome data. The 2024 Endocrine Society update 440 retreated from routine 25-OH-D screening and empiric supplementation in generally healthy adults; it retained replacement of documented deficiency, age-specific empiric supplementation in children 1, 18 and pregnant individuals, and a conditional recommendation in prediabetes.
Compounded vitamin D is not FDA-approved. Compounded preparations under 503A are dispensed only on patient-specific prescription where the OTC or branded prescription products cannot meet a documented clinical need, for example, absorption-impaired patients (cystic fibrosis, post-bariatric), pediatric custom liquid dropper concentrations, or high-dose IM stoss therapy.
Compounded use
Compounded High-Dose Vitamin D (503A)
Honest framing first: vitamin D3 (cholecalciferol) is the substance with the broadest OTC availability of any compound on the RonanRx 503A formulary. Strengths up to 50,000 IU per softgel are sold without prescription as dietary supplements. Most adults who need vitamin D supplementation are appropriately served by OTC cholecalciferol at IOM-RDA-consistent or modestly higher daily doses, with the 2024 Endocrine Society guideline supporting this default in generally healthy adults 2420. The compounded 503A role is therefore narrow and patient-specific.
Documented clinical reasons that justify a compounded preparation include: (1) fat-soluble vitamin malabsorption, cystic fibrosis, post-Roux-en-Y or biliopancreatic-diversion bariatric surgery, short bowel syndrome, chronic pancreatic insufficiency, where oil-based, liposomal, or IM-injectable preparations may improve absorption beyond what an OTC softgel achieves 3; (2) pediatric individualization, custom-strength liquid drops for infants and children outside the standard 400 IU/dose drug-product range, particularly where rickets prevention or treatment requires precise titration 9; (3) very-high-dose IM stoss therapy where bolus IM cholecalciferol replaces unreliable oral dosing, typically reserved for severe deficiency in adherence-limited or absorption-impaired patients, with appropriate monitoring against the Sanders 2010 cautionary signal that bolus size and pharmacology matter 11; (4) sublingual or troche dosing for patients with oral aversion or swallowing difficulties; (5) preservative- or excipient-sensitivity to commercial softgels (rare). Cost or convenience does not qualify as a 503A justification, and for vitamin D specifically, OTC cholecalciferol is rarely more expensive than a compounded preparation 1923.
Prescription FDA-approved alternatives must be considered before compounding. Drisdol (ergocalciferol 50,000 IU) covers most weekly high-dose replacement, though Trang 1998 5 supports cholecalciferol as the kinetically preferred form. Rocaltrol (calcitriol) and Hectorol (doxercalciferol) are reserved for renal disease with impaired 1α-hydroxylation 2829 and should not be substituted for parental D2/D3 in patients with normal kidney function.
Compounded vitamin D preparations are not FDA-approved and are not bioequivalent to commercially available cholecalciferol softgels or to prescription ergocalciferol or calcitriol. Stability and bioavailability of compounded oily, liposomal, sublingual, or IM-injectable cholecalciferol preparations depend on the specific formulation and have not been tested in efficacy RCTs. Compounded preparations are typically not appropriate for general 'wellness' or empiric high-dose supplementation in replete adults, given the consistent null large-RCT supplementation literature 2124.
Formulations and routes
High-Dose Vitamin D Formulations and Routes
Form
Concentration
Description
Compounded oral capsule or softgel (cholecalciferol)
Custom, typically 5,000, 50,000 IU per capsule; rarely 100,000 IU/capsule for documented severe deficiency
Compounded oral cholecalciferol prepared under USP <795> for patient-specific dosing or excipient profile not available OTC.32
Custom, typically 1,000, 10,000 IU per drop in MCT or olive oil vehicle
Pediatric and absorption-impaired dosing; oil vehicle improves fat-soluble carrier absorption. Beyond-use date assigned per USP <795>.329
Compounded sterile intramuscular injection (cholecalciferol or ergocalciferol)
Custom, typically 100,000, 600,000 IU per dose in sesame or peanut oil vehicle for IM bolus (stoss) therapy
IM injection reserved for documented severe deficiency in malabsorption phenotypes or adherence-limited settings. Prepared under USP <797>; oil vehicle requires deep IM administration.3310
Compounded sublingual or troche (cholecalciferol)
Custom, typically 1,000, 10,000 IU per dose
Sublingual / buccal preparation for patients with swallowing difficulty or oral aversion. Bioavailability vs oral softgel is not well characterized in published trials.32
Institute of Medicine 2011 dietary reference intake2
Oral
Adults, Endocrine Society 2011 maintenance
1,500, 2,000 IU/day cholecalciferol to maintain 25-OH-D >30 ng/mL; up to 10,000 IU/day tolerable upper intake for adults
Indefinite maintenance
Endocrine Society 2011 clinical practice guideline (conflicting with IOM)37
Oral
Adults with documented 25-OH-D deficiency (<20 ng/mL)
50,000 IU ergocalciferol weekly for 8, 12 weeks, or 6,000 IU/day cholecalciferol for 8 weeks, until 25-OH-D >30 ng/mL; then 1,500, 2,000 IU/day maintenance
8, 12 weeks loading; indefinite maintenance
Endocrine Society 2011 guideline; FDA-approved Drisdol regimen327
Oral
Children 0, 1 year (rickets prevention)
400 IU/day cholecalciferol from birth
Through age 12 months
Lawson Wilkins Pediatric Endocrine Society consensus; IOM RDA92
Oral
Children 1, 18 (rickets prevention)
600 IU/day cholecalciferol
Indefinite through adolescence
IOM RDA; Endocrine Society 2024 guideline supports higher empiric dosing in this age group249
Oral
Pregnant adults
Standard prenatal 400 IU/day; Hollis 2011 RCT supports 4,000 IU/day as safer and more effective at achieving 25-OH-D sufficiency. 2024 Endocrine Society guideline supports daily supplementation above standard prenatal dose.
Throughout pregnancy
Phase III RCT (Hollis 2011); Endocrine Society 2024 guideline144
Oral
Adults with chronic kidney disease (calcitriol, Rocaltrol)
0.25 mcg orally once daily, titrated by 0.25 mcg every 4, 8 weeks to a maximum of 0.5, 1.0 mcg/day based on serum calcium and PTH
Adults with documented severe deficiency or malabsorption (compounded IM stoss)
Compounded cholecalciferol 100,000, 600,000 IU IM as a single bolus or quarterly; serum 25-OH-D rechecked at 8, 12 weeks. Annual 500,000 IU IM/oral is not recommended (Sanders 2010 paradoxical falls/fractures).
Single bolus or quarterly
Compounded preparation; supported by Trivedi 2003 four-monthly oral 100,000 IU; cautioned by Sanders 2010 annual 500,000 IU1011
Vitamin D dosing is doctor-prescribed and titrated against serum 25-hydroxyvitamin D, not 1,25-dihydroxyvitamin D. The Heaney 2003 6 dose-response relationship, approximately 0.7 ng/mL increment in steady-state 25-OH-D per 100 IU/day cholecalciferol, supports a rational titration: a 20 ng/mL deficit closes on approximately 2,500, 3,000 IU/day at steady state over 6, 12 weeks. Loading doses (50,000 IU ergocalciferol weekly for 8, 12 weeks, or 6,000 IU/day cholecalciferol for 8 weeks) accelerate this trajectory but do not change the steady-state target. The Trang 1998 5 comparison favors cholecalciferol (D3) over ergocalciferol (D2) at equimolar dosing.
Compounded preparations should mirror these dose ranges. The exception is malabsorption-phenotype patients, where oral doses 5, 10× the daily replacement range may be needed to achieve sufficiency 3, and where IM stoss therapy may be considered when oral absorption is unreliable. Bolus pharmacology has a documented safety inflection: four-monthly 100,000 IU is acceptable 10; annual 500,000 IU is harmful 11. Compounded IM stoss preparations should not exceed quarterly 100,000, 300,000 IU without specific documented clinical rationale.
Active analogs (calcitriol, doxercalciferol) bypass the renal 1α-hydroxylation step and are reserved for chronic kidney disease and hereditary 1α-hydroxylase deficiency. They are not substitutable for cholecalciferol or ergocalciferol in patients with normal kidney function and carry a much narrower therapeutic window 2829.
Doses listed are literature context, not patient instructions. Dosing decisions are made by the prescribing doctor and tailored to the individual patient.
Safety
High-Dose Vitamin D Safety
Safety overview
Vitamin D in physiologic doses has a wide therapeutic window. The IOM 2011 2 tolerable upper intake is 4,000 IU/day for adults; the Hathcock 2007 7 risk assessment supports up to 10,000 IU/day chronically in adults without increased risk of hypercalcemia, hypercalciuria, or nephrocalcinosis when 25-OH-D remains below approximately 150 ng/mL. Documented vitamin D toxicity (hypervitaminosis D) is reliably observed only at sustained intake far above the upper intake or at 25-OH-D levels typically >150 ng/mL, and is dominated by hypercalcemia and its consequences (polyuria, dehydration, nephrocalcinosis, nephrolithiasis, soft-tissue calcification). Case reports of toxicity overwhelmingly follow megadose dispensing errors, manufacturing errors (mislabeled supplements), or pulse-dosing accidents, not chronic daily intake at guideline-consistent doses.
Bolus pharmacology has a documented safety inflection. Sanders 2010 11 randomized 2,256 community-dwelling older women to an annual 500,000 IU oral cholecalciferol bolus or placebo and reported a 26% increase in falls and a 26% increase in fractures over a median 3 years, the opposite of the intended effect. Trivedi 2003 10 of a four-monthly 100,000 IU bolus did not produce excess events. The mechanism remains debated (transient supraphysiologic peaks, impact on vitamin D binding protein, vestibular effects) but the prescribing implication is clear: annual or larger boluses should not be used. Compounded IM stoss preparations should respect this ceiling.
Drug-induced hypercalcemia is the principal toxicity. It is more readily seen with calcitriol and doxercalciferol than with parental D2/D3 because the active analogs bypass the regulated renal 1α-hydroxylation step; manufactured-product labeling for Rocaltrol and Hectorol 2829 requires close monitoring of serum calcium, phosphate, and PTH. Granulomatous disease (sarcoidosis, tuberculosis) and CYP24A1 loss-of-function (idiopathic infantile hypercalcemia) produce extrarenal calcitriol synthesis that escapes feedback, and vitamin D supplementation in these conditions can precipitate severe hypercalcemia.
Large supplementation RCTs in generally healthy adults have not raised broad safety signals. VITAL 1920, ViDA 2122, D-Health, DO-HEALTH 24, and D2d 23 reported no excess kidney stones, fractures, or major adverse events at daily doses up to 4,000 IU or monthly boluses up to 100,000 IU; the principal safety inflections remain (a) annual mega-boluses and (b) the granulomatous and CYP24A1 subpopulations identified above.
Contraindications
Vitamin D supplementation is contraindicated in: established hypercalcemia (regardless of cause); active hypervitaminosis D or 25-OH-D >150 ng/mL; known hypersensitivity to the specific preparation or excipient. Active analogs (calcitriol, doxercalciferol) are additionally contraindicated in any condition associated with hypercalcemia or vitamin D toxicity, and require especially cautious use in patients with reduced GFR or on calcium-containing phosphate binders 28291.
Caution is required in granulomatous disease (sarcoidosis, tuberculosis, fungal infections) and in patients with CYP24A1 or SLC34A1 mutations (idiopathic infantile hypercalcemia), where extrarenal or unregulated calcitriol synthesis can produce hypercalcemia with supplementation that would be safe in unaffected patients. Williams syndrome is similarly hypercalcemia-prone. Calcium-channel-blocker overdose or thiazide diuretic use can compound hypercalcemia risk from vitamin D supplementation 1.
Drug interactions
Pharmacokinetic interactions: agents that induce CYP3A4 (rifampin, phenytoin, phenobarbital, carbamazepine, St. John's wort) and CYP24A1 accelerate 25-OH-D and 1,25-(OH)2-D catabolism, lowering serum 25-OH-D and potentially requiring higher replacement doses. Cholestyramine, colestipol, orlistat, and mineral oil reduce intestinal absorption of fat-soluble vitamins including cholecalciferol. Ketoconazole and similar azoles inhibit CYP27B1 and reduce 1,25-(OH)2-D synthesis.
Pharmacodynamic interactions: thiazide diuretics increase renal calcium reabsorption and can precipitate hypercalcemia in patients on vitamin D supplementation. Calcium-containing phosphate binders and oral calcium supplements compound hypercalcemia risk, particularly with calcitriol or doxercalciferol 2829. Digoxin toxicity is potentiated by vitamin-D-associated hypercalcemia. Aluminum-containing antacids and phosphate binders may have increased aluminum absorption in the setting of vitamin D supplementation 1.
Adverse events
At guideline-consistent daily intake (≤4,000 IU/day cholecalciferol), vitamin D supplementation is well tolerated. The large supplementation RCTs reported no excess adverse events. VITAL 1920 (2,000 IU/day cholecalciferol over 5.3 years, N=25,871) reported no excess hypercalcemia, kidney stones, or other adverse events. ViDA 2122 (monthly 100,000 IU over a median 3.3 years, N=5,108), D2d 23 (4,000 IU/day, N=2,423), and DO-HEALTH 24 (2,000 IU/day, N=2,157) reported similarly clean safety profiles.
Hypercalcemia is the dose-limiting toxicity at supra-physiologic intake. Symptoms range from polyuria, polydipsia, anorexia, nausea, and constipation at mild elevations to dehydration, confusion, arrhythmia, nephrocalcinosis, nephrolithiasis, and acute kidney injury at severe elevations. Hypercalciuria precedes hypercalcemia and is a useful sentinel. The Sanders 2010 11 annual 500,000 IU bolus paradoxically increased falls and fractures; the mechanism is unsettled but the prescribing implication holds.
Idiosyncratic and rare events: hypersensitivity to specific compounded excipients or oil vehicles (sesame, peanut) can occur, particularly with IM preparations, careful allergy history is required. IM injection-site reactions (induration, sterile abscess) are reported with oily IM stoss preparations. Calcitriol and doxercalciferol carry a narrower therapeutic window and require frequent calcium, phosphate, and PTH monitoring per manufactured-product labeling 2829.
Monitoring
Monitoring High-Dose Vitamin D Therapy
Baseline assessment in patients prescribed therapeutic-dose vitamin D should include serum 25-hydroxyvitamin D (not 1,25-(OH)2-D), serum calcium, phosphate, creatinine, and, when active analogs are being considered or there is risk of granulomatous disease, serum 1,25-dihydroxyvitamin D and PTH. The 2024 Endocrine Society guideline 4 does not recommend routine 25-OH-D screening in generally healthy adults; screening is reserved for clinical indication (suspected deficiency, malabsorption, chronic kidney disease, granulomatous disease, abnormal calcium or PTH) 3.
On therapy: recheck serum 25-OH-D at 8, 12 weeks after a dose change or replacement initiation, then every 3, 6 months until stable, then annually 3. For patients on calcitriol or doxercalciferol, serum calcium and phosphate should be measured at least every 2 weeks during dose titration, then less frequently when stable, per manufactured-product labels 2829. For compounded high-dose oral, IM, or stoss preparations, recheck 25-OH-D, calcium, and creatinine 8, 12 weeks after a bolus. The Sanders 2010 11 cautionary signal supports avoiding annual or larger bolus regimens.
Special populations
High-Dose Vitamin D in Special Populations
Pregnancy
Pregnancy is one of the few populations where the 2024 Endocrine Society guideline 4 recommends supplementation above the standard prenatal 400 IU/day. The Hollis 2011 RCT 14 randomized 494 pregnant women to 400, 2,000, or 4,000 IU/day cholecalciferol from 12, 16 weeks gestation through delivery and reported that 4,000 IU/day was safer and more effective than 400 IU/day at achieving 25-OH-D sufficiency in mother and cord blood, without adverse maternal or neonatal events. The accompanying review 15 consolidated pregnancy requirements.
Compounded pediatric drops at the neonatal end of the dispensing chain are commonly prescribed to breastfed infants whose intake of fat-soluble vitamins via breast milk depends on maternal vitamin D status. Misra et al. 9 supports 400 IU/day for all breastfed infants from birth.
Lactation
Vitamin D is transferred into breast milk in small amounts that depend on maternal 25-OH-D status. Standard 400 IU/day maternal supplementation transfers insufficient vitamin D to meet the breastfed infant's 400 IU/day requirement, which is why direct infant supplementation is recommended 9. Maternal supplementation at 4,000, 6,400 IU/day has been studied as an alternative to direct infant supplementation but is not the default approach 154.
Pediatric
Pediatric dosing is the most common 503A compounded use case for vitamin D 2. Standard recommendations: 400 IU/day from birth through 12 months for all breastfed infants; 600 IU/day for children 1, 18 years (IOM RDA, reaffirmed by Demay 2024). Documented deficiency in children is treated with 2,000, 6,000 IU/day cholecalciferol for 6, 12 weeks until 25-OH-D >30 ng/mL, then maintenance 93. The 2024 Endocrine Society guideline 4 supports higher empiric supplementation in children 1, 18 for non-skeletal endpoints (respiratory infection prevention concentrated in deficient children).
Compounded pediatric drops at 400, 1,000, or higher IU per drop in MCT or olive oil vehicle are commonly prescribed for infants and toddlers where the commercial drug-product range does not match the prescriber's intended dose 2. Custom strengths are particularly useful for nutritional rickets treatment, prematurity follow-up, and malabsorption phenotypes.
Geriatric
Older adults have reduced cutaneous vitamin D synthesis (~75% decline by age 70 vs age 20 at matched UVB exposure), increased prevalence of low 25-OH-D, and elevated fall and fracture risk. The IOM 2011 2 RDA is 800 IU/day for adults >70; the 2024 Endocrine Society guideline 4 supports empiric supplementation in adults ≥75 for skeletal benefit. Bischoff-Ferrari's 2009 falls meta-analysis 12 and 2012 fracture pooled analysis 13 supported ≥800 IU/day in vitamin-D-deficient older adults; modern large RCTs in replete older adults (DO-HEALTH 24, VITAL fracture ancillary 20) have been null.
Annual bolus regimens should be avoided in older adults given the Sanders 2010 11 signal of increased falls and fractures at annual 500,000 IU.
Renal impairment
Chronic kidney disease impairs renal 1α-hydroxylation; serum 25-OH-D may be preserved while 1,25-(OH)2-D falls, contributing to secondary hyperparathyroidism and renal osteodystrophy. The pre-hydroxylated active analogs calcitriol (Rocaltrol/Calcijex) and doxercalciferol (Hectorol) 2829 are FDA-approved for this indication and require frequent serum calcium, phosphate, and PTH monitoring. Parental D2/D3 supplementation remains appropriate for 25-OH-D repletion in CKD but does not address the downstream activation deficit 1.
Hepatic impairment
Severe hepatic impairment reduces 25-hydroxylation capacity, but clinically significant 25-OH-D deficiency from this mechanism is uncommon outside of advanced cirrhosis. Patients with severe cholestasis may have additional fat-soluble vitamin malabsorption and may require higher-dose or parenteral replacement. Active analog dosing is not specifically adjusted for hepatic impairment per the manufactured-product labels 2829.
Evidence quality
High-Dose Vitamin D Evidence Quality
Evidence quality for vitamin D is bifurcated. Mechanistic biology (skin synthesis, hepatic 25-hydroxylation, renal 1α-hydroxylation, VDR signaling, PTH/FGF-23/CYP24A1 feedback) is robust, and the dose-response of serum 25-OH-D to oral cholecalciferol is well characterized 65. Replacement of documented deficiency to skeletal benefit is supported by IOM and Endocrine Society guidelines 234 and by population-specific RCTs and meta-analyses in older adults 1213.
Evidence for empiric supplementation in generally healthy adults to prevent cancer, cardiovascular disease, fracture, or progression to diabetes is consistently null across the largest RCTs ever conducted. VITAL 1920 (N=25,871, 5.3 years, 2,000 IU/day), ViDA 2122 (N=5,108, monthly 100,000 IU), D2d 23 (N=2,423, 4,000 IU/day in prediabetes), and DO-HEALTH 24 (N=2,157, 2,000 IU/day in healthy older adults) all reported null primary endpoints. The Lappe 2017 25 vitamin D plus calcium cancer prevention trial was likewise null. Bolland's 2018 26 meta-analysis of 81 RCTs concluded against routine supplementation for fracture/falls prevention in unselected adults. The 2024 Endocrine Society guideline 4 formalized this retreat from broad empiric supplementation and screening.
Specific subgroup signals retain support: respiratory tract infection prevention in deficient patients on daily low-dose regimens 1617; rickets and osteomalacia prevention in children and pregnant adults 914; and active analog therapy in chronic kidney disease 2829. The Sanders 2010 11 annual-bolus paradoxical harm and Trivedi 2003 10 four-monthly bolus signal bracket the safe upper limit of pulse-dose pharmacology.
Evidence specifically supporting compounded preparations is absent, there is no parallel efficacy program for compounded oral, IM, or sublingual cholecalciferol or ergocalciferol. Compounded use in malabsorption phenotypes (cystic fibrosis, post-bariatric, short bowel) extrapolates from the manufactured-product replacement literature, justified case by case by the documented inability of OTC oral cholecalciferol to achieve 25-OH-D sufficiency in the individual patient 37.
Canonical clinical review of vitamin D physiology, pathophysiology, worldwide deficiency prevalence, and supplementation strategy 1. Established the modern framework for clinical decision-making.
Defined deficiency as <20 ng/mL and insufficiency as 21, 29 ng/mL with >30 ng/mL target; recommended higher daily intake (1,500, 2,000 IU/day) and screening of at-risk groups 3. Conflicted with IOM thresholds.
Updated Endocrine Society clinical practice guideline
—
—
Retreated from routine 25-OH-D screening and broad empiric supplementation in generally healthy adults. Reserved empiric supplementation for children 1, 18, pregnancy, adults ≥75, and prediabetes (conditional). Reaffirmed replacement of documented deficiency 4.
Randomized comparison of equimolar oral D3 and D2 supplementation on serum 25-OH-D in healthy adults
—
—
Cholecalciferol (D3) raised serum 25-OH-D approximately twice as efficiently as ergocalciferol (D2) at equimolar dosing 5. Kinetic basis for the modern preference for D3.
Healthy-adult dose-finding study of oral cholecalciferol vs serum 25-OH-D
—
—
Approximately 0.7 ng/mL increment in steady-state serum 25-OH-D per 100 IU/day of D3 across the physiologic range 6. Empirical basis for clinical titration math.
Quantitative risk assessment integrating dose-response and adverse-event data
—
—
Supported a tolerable upper intake of 10,000 IU/day cholecalciferol in adults without increased risk of hypercalcemia, hypercalciuria, or nephrocalcinosis 7. Higher than the IOM 2011 4,000 IU/day, providing competing safety frame.
Dose-response analysis of cholecalciferol intake required to reach defined 25-OH-D thresholds
—
—
Reaching 25-OH-D >30 ng/mL required intakes well above the IOM RDA in many adults, particularly Black Americans with lower baseline 25-OH-D. Supported population-specific dose recommendations 8.
Phase III randomized double-blind placebo-controlled RCT in community-dwelling older women
2256
Median 3 years
Annual 500,000 IU oral cholecalciferol paradoxically increased falls (rate ratio 1.15, 95% CI 1.02, 1.30) and fractures (rate ratio 1.26, 95% CI 1.00, 1.59) 11. Established the bolus-size safety inflection.
Pooled participant-level analysis of 11 double-blind RCTs of oral vitamin D supplementation in older adults
31022
—
Highest actual-intake quartile (median 800 IU/day) reduced hip fracture by 30% (HR 0.70, 95% CI 0.58, 0.86) and non-vertebral fracture by 14% vs lowest quartile. Supported daily 800 IU/day in older adults for fracture prevention 13.
Phase III randomized double-blind RCT in pregnant women from 12, 16 weeks gestation
494
Through delivery
4,000 IU/day cholecalciferol achieved 25-OH-D sufficiency in 82% vs 50% of the 400 IU/day arm with no adverse maternal or neonatal events. Cord blood 25-OH-D rose in parallel 14.
Phase III randomized double-blind placebo-controlled trial of 2,000 IU/day cholecalciferol vs placebo (factorial with omega-3) in generally healthy U.S. adults
25871
Median 5.3 years
Null primary endpoints: invasive cancer (HR 0.96, 95% CI 0.88, 1.06) and major cardiovascular events (HR 0.97, 95% CI 0.85, 1.12) 19. Largest vitamin D supplementation RCT ever conducted.
Pre-specified ancillary of VITAL, incident fractures over the full follow-up
25871
Median 5.3 years
2,000 IU/day cholecalciferol did not reduce incident total fracture (HR 0.98, 95% CI 0.89, 1.08), non-vertebral fracture, or hip fracture in midlife and older adults 20. Closed the question of empiric supplementation for fracture prevention in replete adults.
Phase III randomized double-blind placebo-controlled trial of monthly 100,000 IU cholecalciferol vs placebo in adults aged 50, 84 in New Zealand
5108
Median 3.3 years
Null on the primary endpoint of incident cardiovascular disease (HR 1.02, 95% CI 0.87, 1.20) 21. Bolus-monthly dosing did not show cardiovascular benefit.
Phase III randomized double-blind placebo-controlled trial of 4,000 IU/day cholecalciferol vs placebo in adults at high risk for type 2 diabetes
2423
Median 2.5 years
Null on the primary endpoint of progression to type 2 diabetes (HR 0.88, 95% CI 0.75, 1.04, P=0.12) 23. Supports a conditional supplementation recommendation in prediabetes per Demay 2024 but no broader claim.
2×2×2 factorial randomized placebo-controlled trial of 2,000 IU/day cholecalciferol, 1 g/day omega-3, and a home exercise program in generally healthy older adults across five European countries
2157
3 years
Null on the composite of musculoskeletal and cognitive function. Vitamin D alone did not improve any individual endpoint vs placebo 24.
Systematic review, meta-analysis, and trial sequential analysis of 81 RCTs of vitamin D supplementation for musculoskeletal outcomes
53537
—
No effect on total fracture, hip fracture, or falls. Bone density effects were small and unlikely to be clinically meaningful. Argued against routine supplementation for musculoskeletal benefit in unselected adults 26.
Lawson Wilkins Pediatric Endocrine Society Drug and Therapeutics Committee consensus review
—
—
400 IU/day from birth for breastfed infants; 600 IU/day for children 1, 18; treatment of established deficiency with 2,000, 6,000 IU/day cholecalciferol for 6, 12 weeks 9. Standard-of-care for pediatric rickets prevention and treatment.
Mechanism detail
Detailed Mechanism of High-Dose Vitamin D
Cutaneous synthesis. UVB photons (290, 315 nm) penetrate the epidermis and cleave the B-ring of 7-dehydrocholesterol to form pre-vitamin D3, which undergoes spontaneous thermal isomerization over hours to cholecalciferol. Excess UVB exposure inactivates pre-vitamin D3 and cholecalciferol to lumisterol and tachysterol, preventing photo-toxicity. Skin pigmentation, latitude, season, sunscreen use, and age modulate cutaneous production; the 25-OH-D output of one minimal erythemal dose of summer sun in a light-skinned adult is roughly equivalent to ingesting 10,000, 25,000 IU of cholecalciferol 1.
Hepatic 25-hydroxylation by CYP2R1 (primary), CYP27A1, and others is largely non-rate-limiting at normal substrate loads, so circulating 25-OH-D rises approximately linearly with cumulative intake of D3 across the physiologic range. Heaney and colleagues 6 characterized the 25-OH-D dose response curve to oral cholecalciferol in healthy adults, establishing that each 100 IU/day of D3 raises steady-state 25-OH-D by approximately 0.7 ng/mL after several weeks of dosing, the empirical basis for dose-titration recommendations. Trang and colleagues 5 demonstrated that cholecalciferol (D3) raises serum 25-OH-D approximately twice as efficiently as ergocalciferol (D2) at equimolar dosing, the kinetic basis for the modern preference for D3 over D2 in supplementation 2423.
Renal 1α-hydroxylation by CYP27B1 is the tightly regulated step. PTH and hypocalcemia upregulate CYP27B1; FGF-23 and 1,25-(OH)2-D itself downregulate it. CYP24A1 catabolizes both 25-OH-D and 1,25-(OH)2-D to inactive 24,25-(OH)2-D and calcitroic acid. In chronic kidney disease, declining functional nephron mass reduces renal CYP27B1 activity and 1,25-(OH)2-D production despite often-preserved 25-OH-D levels, the rationale for active analogs (calcitriol, doxercalciferol) bypassing the diseased step 2829.
VDR signaling. The 1,25-(OH)2-D/VDR/RXR complex binds vitamin D response elements (VDREs) in target gene promoters across more than a thousand annotated loci. Classical targets include TRPV6 (intestinal calcium absorption), calbindin-D9k and -D28k (calcium buffering), and CYP24A1 (feedback degradation). Non-classical targets include cathelicidin (innate immune defense), CYP3A4 (xenobiotic metabolism), and a constellation of immune and proliferation genes that drove enthusiasm for vitamin D as a potential preventive in cancer, cardiovascular disease, and autoimmunity, enthusiasm that the large RCTs of the past decade have largely deflated 1921.
Pharmacology
High-Dose Vitamin D Pharmacokinetics & Pharmacodynamics
Pharmacokinetics
Cholecalciferol (D3) and ergocalciferol (D2) are absorbed primarily via passive diffusion in the proximal small intestine, packaged into chylomicrons, and transported in the lymphatic circulation before entering the systemic circulation. Oral bioavailability of D3 in oily vehicles is approximately 60, 80% in healthy adults and substantially lower in fat-malabsorption phenotypes. After 25-hydroxylation in the liver, 25-OH-D is bound predominantly to vitamin D binding protein (DBP, ~85%) and albumin (~15%) and has a terminal half-life of approximately 15, 30 days, supporting daily, weekly, and four-monthly dosing intervals 1.
1,25-(OH)2-D (calcitriol) has a much shorter half-life of approximately 4, 6 hours and is tightly regulated by PTH, FGF-23, and feedback through CYP24A1 1. Therapeutic calcitriol (Rocaltrol oral or Calcijex IV) achieves Cmax within 3, 6 hours of an oral dose; doxercalciferol (Hectorol) is a prodrug requiring hepatic 25-hydroxylation to 1α,25-(OH)2-D2 with onset over 24, 48 hours 2829.
The Heaney 2003 6 dose-response curve characterizes the steady-state 25-OH-D response to oral cholecalciferol, approximately 0.7 ng/mL per 100 IU/day 1. Trang 1998 5 demonstrated that D3 raises 25-OH-D approximately twice as efficiently as D2 at equimolar dosing, attributable to higher affinity of D3 metabolites for DBP and slower catabolism.
Compounded preparations may differ from manufactured products in vehicle (oil type, liposomal, sublingual), beyond-use date, and concentration; bioavailability of compounded oily IM preparations, sublingual drops, and troches has not been characterized in published PK studies 1. Stability of cholecalciferol in compounded preparations depends on oxygen exposure, light, and temperature.
Pharmacodynamics
The clinically measured pharmacodynamic endpoint is serum 25-hydroxyvitamin D (25-OH-D), with calcium, phosphate, PTH, and (in active-analog therapy) serum 1,25-(OH)2-D as adjuncts. Steady-state 25-OH-D rises approximately linearly with daily cholecalciferol dose across the physiologic range 62426. PTH suppression and intestinal calcium absorption follow the 25-OH-D curve with thresholds debated between the IOM and Endocrine Society guidelines 2320.
Hard clinical endpoints (fracture, falls, cancer incidence, cardiovascular events, type 2 diabetes progression) have repeatedly failed to track the 25-OH-D rise in large RCTs of supplementation in replete populations, although replacement in documented deficiency retains support 192123.
Comparative formulations
Comparing High-Dose Vitamin D Formulations
Cholecalciferol (D3) is the kinetically preferred form for parental vitamin D supplementation: D3 raises 25-OH-D approximately twice as efficiently as D2 at equimolar dosing 5. OTC cholecalciferol softgels and tablets in the 1,000, 10,000 IU/day range cover the majority of supplementation needs at lower cost than any prescription or compounded alternative.
Prescription ergocalciferol (Drisdol 50,000 IU capsule) remains common for weekly high-dose replacement 27, although equivalent OTC cholecalciferol (e.g., 50,000 IU softgel) is generally preferred on PK grounds 5. Calcitriol (Rocaltrol/Calcijex) and doxercalciferol (Hectorol) are pre-hydroxylated active analogs reserved for chronic kidney disease and hereditary 1α-hydroxylase deficiency 2829; they carry a narrow therapeutic window and are not substitutable for parental D2/D3 in patients with normal kidney function.
Compounded preparations cover specific niches: oil-based or liposomal oral formulations for fat-malabsorption phenotypes; pediatric drops at custom strengths; sublingual or troche dosing for swallowing difficulty; and IM injection for stoss therapy in adherence- or absorption-limited patients. Compounded preparations are not bioequivalent to manufactured products and have not been characterized in efficacy RCTs.
Storage
High-Dose Vitamin D Storage and Handling
Cholecalciferol and ergocalciferol are stable at controlled room temperature (20, 25°C) when protected from light and oxygen. Oil-vehicle preparations (softgels, compounded oily liquids, IM injections) extend stability but introduce oxidative degradation risk when seals are broken; light exposure accelerates degradation. Manufactured products (Drisdol, OTC softgels) are labeled for ambient storage; compounded preparations are storage-labeled per the pharmacy's stability data and beyond-use date assignment under USP <795> (nonsterile) or USP <797> (sterile injectables) 3233.
Compounded sterile IM injectable cholecalciferol or ergocalciferol is typically refrigerated and protected from light during storage 33. Calcitriol oral capsules (Rocaltrol) are stored at room temperature in the original light-protected container; Calcijex IV ampoules are similarly light-protected 28.
RonanRx operations
High-Dose Vitamin D Compounding & Operations
503A compounding
Compounded vitamin D preparations are prepared under 503A on patient-specific prescriptions in state-licensed compounding pharmacies 30. Nonsterile preparations (oral capsules, oily liquid drops, troches, sublingual drops) are prepared under USP General Chapter <795>; sterile injectable preparations (IM cholecalciferol or ergocalciferol stoss) are prepared under USP General Chapter <797> with documented active-ingredient sourcing, gravimetric and analytical verification, sterility and endotoxin testing per the pharmacy's quality-management system, and full lot traceability 3233.
Beyond-use dating, ingredient identity verification, and stability assessment follow USP <795>/<797> requirements. Each compounded batch is documented per state board of pharmacy retention rules with full traceability from API lot through dispensing. Cholecalciferol and ergocalciferol APIs are sourced from FDA-registered facilities with documented certificates of analysis; assay verification is particularly important given the wide strength range (400 IU to 50,000 IU+ per dose) and the megadose-error case reports in the literature.
Pharmacist review
Each prescription for compounded vitamin D undergoes pharmacist review prior to dispensing. The review confirms: a documented patient-specific clinical reason that OTC cholecalciferol or the FDA-approved prescription alternatives (Drisdol, Rocaltrol, Hectorol) are not appropriate, typically fat-soluble vitamin malabsorption, pediatric dose individualization outside commercial drug-product strengths, oral aversion / swallowing difficulty, or documented severe deficiency requiring IM stoss in adherence-limited settings; absence of contraindications (active hypercalcemia, 25-OH-D >150 ng/mL, granulomatous disease without specialist co-management, CYP24A1-related hypercalcemia); and a prescribed regimen consistent with guideline-supported titration math 6 rather than annual mega-bolus pharmacology 11327.
RonanRx does not fill prescriptions that read as routine substitution of compounded for OTC cholecalciferol without documented clinical rationale. Particular scrutiny applies to: requests for very-high-dose oral or IM preparations without baseline 25-OH-D documentation; requests for calcitriol or doxercalciferol substitution in patients without renal indication; and any prescription pattern consistent with empiric high-dose supplementation in replete adults given the consistent null large-RCT supplementation literature 192042829.
Quality and traceability
Cholecalciferol and ergocalciferol APIs are sourced from FDA-registered facilities with documented certificates of analysis. Each compounded batch is recorded with lot numbers traceable to API source, compounding date, beyond-use date, assay verification, (where sterile) sterility and endotoxin test result, and dispensing pharmacist of record. Finished product lot records are retained per state board of pharmacy retention requirements. Particular care is taken with assay verification given the wide strength range (400 IU to 50,000 IU+ per dose) and the documented case-report history of megadose dispensing errors.
Cold chain
Compounded cholecalciferol oral capsules, drops, and troches are shipped at controlled room temperature with light protection; oil-vehicle preparations are particularly sensitive to oxidative degradation when seals are compromised. Compounded sterile IM injectable cholecalciferol or ergocalciferol is shipped refrigerated with temperature monitoring through the shipment. Patients are advised to inspect for temperature excursions on receipt and to contact the pharmacy if cold-chain integrity is in question.
FAQ
Frequently Asked Questions About High-Dose Vitamin D
Why would I need compounded vitamin D when D3 is sold over the counter?
Most adults do not. OTC cholecalciferol at 1,000, 5,000 IU/day covers the majority of supplementation needs and is generally preferred over compounded preparations on both cost and PK grounds. The compounded role is narrow: fat-soluble vitamin malabsorption (cystic fibrosis, post-bariatric surgery, short bowel), pediatric drops at custom strengths, oral aversion or swallowing difficulty, and IM stoss therapy for documented severe deficiency in adherence-limited settings 3. RonanRx does not fill compounded vitamin D prescriptions that read as routine substitution for OTC cholecalciferol 24.
What is the difference between vitamin D2 and vitamin D3?
Vitamin D2 (ergocalciferol) is produced from yeast or fungus; vitamin D3 (cholecalciferol) is produced in mammalian skin under UVB or commercially from sheep wool lanolin. The Trang 1998 trial demonstrated that D3 raises serum 25-OH-D approximately twice as efficiently as D2 at equimolar dosing, which is why D3 is the kinetically preferred form for supplementation 5. Prescription Drisdol is D2 at 50,000 IU per capsule; equivalent OTC D3 softgels are generally preferred 27.
How much vitamin D should an adult take?
The IOM 2011 RDA is 600 IU/day for ages 1, 70 and 800 IU/day for >70, with a 4,000 IU/day tolerable upper intake. The Endocrine Society 2011 guideline recommended a higher target (1,500, 2,000 IU/day) to maintain serum 25-OH-D above 30 ng/mL. The 2024 Endocrine Society guideline retreated from broad screening and empiric supplementation in generally healthy adults 34. For documented deficiency (25-OH-D <20 ng/mL), 50,000 IU ergocalciferol weekly for 8, 12 weeks or 6,000 IU/day cholecalciferol for 8 weeks is a standard loading regimen 2.
Does vitamin D prevent cancer, heart disease, or fractures?
Not in generally healthy adults, based on the largest RCTs. VITAL (25,871 U.S. adults, 2,000 IU/day, 5.3 years) was null for invasive cancer, major cardiovascular events, and incident fractures 20. ViDA (5,108 NZ adults, monthly 100,000 IU) was null for cardiovascular disease and falls 1921. D2d was null for progression to type 2 diabetes in prediabetes 23. DO-HEALTH was null in healthy older adults 24. Replacement in documented deficiency retains support for skeletal endpoints, particularly in older adults at risk for fracture.
What is the highest dose that is safe to take long-term?
The IOM tolerable upper intake is 4,000 IU/day; the Hathcock 2007 risk assessment supported up to 10,000 IU/day in adults without increased risk of hypercalcemia or kidney stones 7. Documented toxicity (hypercalcemia, nephrocalcinosis) is usually associated with sustained intake far above the upper intake or 25-OH-D >150 ng/mL, typically from megadose dispensing errors or chronic mislabeled supplements. Annual mega-bolus dosing (500,000 IU at once) has been linked to paradoxically increased falls and fractures and should be avoided 211.
What's calcitriol and why is it prescription-only?
Calcitriol (Rocaltrol oral, Calcijex IV) is 1,25-dihydroxyvitamin D, the active hormone 28. It bypasses the body's normal regulation at the renal 1α-hydroxylation step and is reserved for chronic kidney disease and hereditary 1α-hydroxylase deficiency, where the regulation is broken 1. It has a narrow therapeutic window for hypercalcemia and requires frequent calcium, phosphate, and PTH monitoring. It is not substitutable for cholecalciferol or ergocalciferol in patients with normal kidney function.
Is supplementation during pregnancy safe?
Yes, in the doses studied. The Hollis 2011 RCT randomized 494 pregnant women to 400, 2,000, or 4,000 IU/day cholecalciferol from 12, 16 weeks gestation through delivery and reported that 4,000 IU/day was safer and more effective at achieving 25-OH-D sufficiency than 400 IU/day, without adverse maternal or neonatal events 14. The 2024 Endocrine Society guideline supports daily supplementation above the standard prenatal 400 IU/day in pregnant individuals 4.
Does RonanRx sell compounded vitamin D directly to patients?
No. Compounded vitamin D requires a patient-specific prescription written by a licensed doctor for an identified patient with a documented clinical reason that the OTC or FDA-approved prescription products are not appropriate, plus pharmacist review before dispensing 31. RonanRx is not a direct-to-consumer storefront, and we do not fill compounded vitamin D prescriptions that read as routine substitution for OTC cholecalciferol 30.
Clinician resource
Download the High-Dose Vitamin D Clinical Monograph (PDF)
The full white paper covers every section on this page plus chemical identity, evidence grading, indication-by-indication summaries, research gaps, and reference appendix. Suitable for sharing with prescribing doctors and pharmacist reviewers.
[holick2007] Holick MF. Vitamin D deficiency.. New England Journal of Medicine. 2007. PMID 17634462. (accessed 2026-05-11)
[rosen_iom2011] Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, et al.. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know.. Journal of Clinical Endocrinology and Metabolism. 2011. PMID 21118827. (accessed 2026-05-11)
[holick_endo2011] Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM, et al.. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline.. Journal of Clinical Endocrinology and Metabolism. 2011. PMID 21646368. (accessed 2026-05-11)
[demay2024] Demay MB, Pittas AG, Bikle DD, Diab DL, Kiely ME, Lazaretti-Castro M, Lips P, Mitchell DM, et al.. Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline.. Journal of Clinical Endocrinology and Metabolism. 2024. PMID 38828931. (accessed 2026-05-11)
[trang1998] Trang HM, Cole DE, Rubin LA, Pierratos A, Siu S, Vieth R. Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2.. American Journal of Clinical Nutrition. 1998. PMID 9771862. (accessed 2026-05-11)
[heaney2003] Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol.. American Journal of Clinical Nutrition. 2003. PMID 12499343. (accessed 2026-05-11)
[hathcock2007] Hathcock JN, Shao A, Vieth R, Heaney R. Risk assessment for vitamin D.. American Journal of Clinical Nutrition. 2007. PMID 17209171. (accessed 2026-05-11)
[aloia2008] Aloia JF, Patel M, Dimaano R, Li-Ng M, Talwar SA, Mikhail M, Pollack S, Yeh JK. Vitamin D intake to attain a desired serum 25-hydroxyvitamin D concentration.. American Journal of Clinical Nutrition. 2008. PMID 18541590. (accessed 2026-05-11)
[misra2008] Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M; Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Vitamin D deficiency in children and its management: review of current knowledge and recommendations.. Pediatrics. 2008. PMID 18676559. (accessed 2026-05-11)
[trivedi2003] Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial.. BMJ. 2003. PMID 12609940. (accessed 2026-05-11)
[sanders2010] Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, Nicholson GC. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial.. JAMA. 2010. PMID 20460620. (accessed 2026-05-11)
[bischofferrari_falls2009] Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, Orav JE, Stuck AE, Theiler R, Wong JB, Egli A, et al.. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials.. BMJ. 2009. PMID 19797342. (accessed 2026-05-11)
[bischofferrari_fracture2012] Bischoff-Ferrari HA, Willett WC, Orav EJ, Lips P, Meunier PJ, Lyons RA, Flicker L, Wark J, et al.. A pooled analysis of vitamin D dose requirements for fracture prevention.. New England Journal of Medicine. 2012. PMID 22762317. (accessed 2026-05-11)
[hollis2011_rct] Hollis BW, Johnson D, Hulsey TC, Ebeling M, Wagner CL. Vitamin D supplementation during pregnancy: double-blind, randomized clinical trial of safety and effectiveness.. Journal of Bone and Mineral Research. 2011. PMID 21706518. (accessed 2026-05-11)
[hollis2011_review] Hollis BW, Wagner CL. Vitamin D requirements and supplementation during pregnancy.. Current Opinion in Endocrinology, Diabetes, and Obesity. 2011. PMID 21857221. (accessed 2026-05-11)
[martineau2017] Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, Dubnov-Raz G, Esposito S, et al.. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data.. BMJ. 2017. PMID 28202713. (accessed 2026-05-11)
[jolliffe2021] Jolliffe DA, Camargo CA Jr, Sluyter JD, Aglipay M, Aloia JF, Ganmaa D, Bergman P, Bischoff-Ferrari HA, et al.. Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials.. Lancet Diabetes and Endocrinology. 2021. PMID 33798465. (accessed 2026-05-11)
[murai2021] Murai IH, Fernandes AL, Sales LP, Pinto AJ, Goessler KF, Duran CSC, Silva CBR, Franco AS, et al.. Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial.. JAMA. 2021. PMID 33595634. (accessed 2026-05-11)
[manson_vital2019] Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, Gibson H, Gordon D, et al.. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease.. New England Journal of Medicine. 2019. PMID 30415629. (accessed 2026-05-11)
[leboff_vital2022] LeBoff MS, Chou SH, Ratliff KA, Cook NR, Khurana B, Kim E, Cawthon PM, Bauer DC, et al.. Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults.. New England Journal of Medicine. 2022. PMID 35939577. (accessed 2026-05-11)
[scragg_vida2017] Scragg R, Stewart AW, Waayer D, Lawes CMM, Toop L, Sluyter J, Murphy J, Khaw KT, et al.. Effect of Monthly High-Dose Vitamin D Supplementation on Cardiovascular Disease in the Vitamin D Assessment Study : A Randomized Clinical Trial.. JAMA Cardiology. 2017. PMID 28384800. (accessed 2026-05-11)
[khaw_vida2017] Khaw KT, Stewart AW, Waayer D, Lawes CMM, Toop L, Camargo CA Jr, Scragg R. Effect of monthly high-dose vitamin D supplementation on falls and non-vertebral fractures: secondary and post-hoc outcomes from the randomised, double-blind, placebo-controlled ViDA trial.. Lancet Diabetes and Endocrinology. 2017. PMID 28461159. (accessed 2026-05-11)
[pittas_d2d2019] Pittas AG, Dawson-Hughes B, Sheehan P, Ware JH, Knowler WC, Aroda VR, Brodsky I, Ceglia L, et al.. Vitamin D Supplementation and Prevention of Type 2 Diabetes.. New England Journal of Medicine. 2019. PMID 31173679. (accessed 2026-05-11)
[bischofferrari_dohealth2020] Bischoff-Ferrari HA, Vellas B, Rizzoli R, Kressig RW, da Silva JAP, Blauth M, Felson DT, McCloskey EV, et al.. Effect of Vitamin D Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes in Older Adults: The DO-HEALTH Randomized Clinical Trial.. JAMA. 2020. PMID 33170239. (accessed 2026-05-11)
[lappe2017] Lappe J, Watson P, Travers-Gustafson D, Recker R, Garland C, Gorham E, Baggerly K, McDonnell SL. Effect of Vitamin D and Calcium Supplementation on Cancer Incidence in Older Women: A Randomized Clinical Trial.. JAMA. 2017. PMID 28350929. (accessed 2026-05-11)
[bolland2018] Bolland MJ, Grey A, Avenell A. Effects of vitamin D supplementation on musculoskeletal health: a systematic review, meta-analysis, and trial sequential analysis.. Lancet Diabetes and Endocrinology. 2018. PMID 30293909. (accessed 2026-05-11)
[fda_essentially_a_copy] U.S. Food and Drug Administration. Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act — Guidance for Industry. FDA Guidance for Industry. 2018. https://www.fda.gov/media/98973/download (accessed 2026-05-11)
[usp_795] United States Pharmacopeia. USP General Chapter <795> Pharmaceutical Compounding — Nonsterile Preparations. USP Compounding Compendium. 2023. https://www.usp.org/compounding/general-chapter-795 (accessed 2026-05-11)
[usp_797] United States Pharmacopeia. USP General Chapter <797> Pharmaceutical Compounding — Sterile Preparations. USP Compounding Compendium. 2023. https://www.usp.org/compounding/general-chapter-797 (accessed 2026-05-11)
[avenell_cochrane2014] Avenell A, Mak JC, O'Connell D. Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men.. Cochrane Database of Systematic Reviews. 2014. PMID 24729336. (accessed 2026-05-11)
[pludowski2023] Płudowski P, Kos-Kudła B, Walczak M, Fal A, Zozulińska-Ziółkiewicz D, Sieroszewski P, Peregud-Pogorzelski J, et al.. Guidelines for Preventing and Treating Vitamin D Deficiency: A 2023 Update in Poland.. Nutrients. 2023. PMID 36771403. (accessed 2026-05-11)
[jolliffe2025] Jolliffe DA, Camargo CA Jr, Sluyter JD, Aglipay M, Aloia JF, Bergman P, Bischoff-Ferrari HA, Borzutzky A, et al.. Vitamin D supplementation to prevent acute respiratory infections: systematic review and meta-analysis of stratified aggregate data.. Lancet Diabetes and Endocrinology. 2025. PMID 39993397. (accessed 2026-05-11)
[wimalawansa2012] Wimalawansa SJ. Vitamin D in the new millennium.. Current Osteoporosis Reports. 2012. PMID 22249582. (accessed 2026-05-11)
[iom2011_full] Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium; Ross AC, Taylor CL, Yaktine AL, Del Valle HB (editors). Dietary Reference Intakes for Calcium and Vitamin D — Institute of Medicine 2011 full report. National Academies Press. 2011. https://www.ncbi.nlm.nih.gov/books/NBK56070/ (accessed 2026-05-11)
Compounded High-Dose Vitamin D is dispensed under 503A on a patient-specific prescription. Pick the path that matches where you're starting from.
For doctors
Offer this medication.
A pharmacist will follow up within two business days. We'll cover state availability, supported formulations, and what integration looks like for your clinic.
If your doctor has already prescribed High-Dose Vitamin D, sign up so we can prepare and ship your medication. The signup wizard collects intake and connects you to the prescribing workflow.
RonanRx prescribes through partner clinics — we don't initiate prescriptions on this site. See how the referral works and how to find a clinic in your state that has evaluated patients for High-Dose Vitamin D.
